Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Advances in the Management of Aggressive Lymphomas
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in the Management of Aggressive Lymphomas

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (15 January 2022) | Viewed by 15054

Special Issue Editors

Prof. Robert A Baiocchi

E-Mail Website
Guest Editor
The Ohio State University James Comprehensive Cancer Center, Columbus, OH, USA
Interests: aggressive lymphoma; mantle cell lymphoma; diffuse large B-cell lymphoma; high grade B-cell lymphoma; targeted therapies; immunotherapy; gene-modified T cells; HIV-associated lymphoma
Dr. Beth Christian

E-Mail Website
Guest Editor
The Ohio State University James Comprehensive Cancer Center, Columbus, OH, USA
Interests: aggressive lymphoma; mantle cell lymphoma; diffuse large B-cell lymphoma; high grade B-cell lymphoma; targeted therapies; immunotherapy; gene-modified T cells; HIV-associated lymphoma

Special Issue Information

Dear Colleagues, 

The lymphomas are a heterogeneous group of hematologic malignancies affecting patients of all age groups and constituting approximately 4.8% of the new cancer cases in the United States. The majority of the lymphomas are considered to be clinically aggressive. While treatment for an aggressive lymphoma traditionally included upfront combination chemotherapy regimens, novel therapies are increasingly being incorporated into the treatment paradigm. Over the past two decades, the rate of death for the two most common types of aggressive lymphoma, diffuse large B-cell lymphoma and classical Hodgkin lymphoma, have declined. Rapid advances in our understanding of disease biology have resulted in the development of targeted treatments, which are largely responsible for the improvement in patient outcomes. This Special Issue will highlight treatment advances in specific aggressive lymphomas with a focus on novel therapeutics including targeted treatments, immunotherapy, and genetically modified T-cell-based therapies.

Prof. Robert A Baiocchi
Dr. Beth Christian
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • aggressive lymphoma
  • mantle cell lymphoma
  • diffuse large B-cell lymphoma
  • high grade B-cell lymphoma
  • targeted therapies
  • immunotherapy
  • gene-modified T cells
  • HIV-associated lymphoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 334 KiB  
Review
Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
by John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel and Jonathan E. Brammer
J. Clin. Med. 2022, 11(10), 2699; https://doi.org/10.3390/jcm11102699 - 10 May 2022
Cited by 9 | Viewed by 3066
Abstract
Extranodal natural killer/T(NK/T)-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma that typically presents with an isolated nasal mass, but a sizeable minority present with advanced stage disease and have a significantly poorer prognosis. Those with limited disease are standardly treated with [...] Read more.
Extranodal natural killer/T(NK/T)-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma that typically presents with an isolated nasal mass, but a sizeable minority present with advanced stage disease and have a significantly poorer prognosis. Those with limited disease are standardly treated with chemotherapy and radiation while those with advanced stage disease are treated with L-asparaginase containing chemotherapy regimens. The addition of modern radiation therapy techniques and the incorporation of L-asparaginase into chemotherapy regimens have significantly improved outcomes in this disease, but relapses and death from relapsed disease remain frequent. Given the high rate of relapse, several novel therapies have been evaluated for the treatment of this disease. In this review, we explore the current standard of care for ENKTL as well as novel therapies that have been evaluated for its treatment and the biologic understanding behind these therapies. Full article
(This article belongs to the Special Issue Advances in the Management of Aggressive Lymphomas)
10 pages, 239 KiB  
Review
HIV-Associated Lymphomas: Progress and New Challenges
by Georgios N. Pongas and Juan C. Ramos
J. Clin. Med. 2022, 11(5), 1447; https://doi.org/10.3390/jcm11051447 - 7 Mar 2022
Cited by 9 | Viewed by 3534
Abstract
The association of human immunodeficiency virus (HIV) and aggressive lymphomas was first reported in 1982. Before the development of effective HIV antiviral therapy, the incidence and the mortality of these lymphomas was high, with patients frequently succumbing to the disease. More lately, the [...] Read more.
The association of human immunodeficiency virus (HIV) and aggressive lymphomas was first reported in 1982. Before the development of effective HIV antiviral therapy, the incidence and the mortality of these lymphomas was high, with patients frequently succumbing to the disease. More lately, the combination of cART with chemoimmunotherapy significantly improved the survival outcome of the HIV-lymphomas. In this review, we discuss on describing the incidence of HIV-associated lymphomas, their clinical features, and the latest advances in the management of the various lymphoma subtypes. Full article
(This article belongs to the Special Issue Advances in the Management of Aggressive Lymphomas)
14 pages, 895 KiB  
Review
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
by David A Bond, Peter Martin and Kami J Maddocks
J. Clin. Med. 2021, 10(6), 1207; https://doi.org/10.3390/jcm10061207 - 14 Mar 2021
Cited by 14 | Viewed by 7611
Abstract
The increasing number of approved therapies for relapsed mantle cell lymphoma (MCL) provides patients effective treatment options, with increasing complexity in prioritization and sequencing of these therapies. Chemo-immunotherapy remains widely used as frontline MCL treatment with multiple targeted therapies available for relapsed disease. [...] Read more.
The increasing number of approved therapies for relapsed mantle cell lymphoma (MCL) provides patients effective treatment options, with increasing complexity in prioritization and sequencing of these therapies. Chemo-immunotherapy remains widely used as frontline MCL treatment with multiple targeted therapies available for relapsed disease. The Bruton’s tyrosine kinase inhibitors (BTKi) ibrutinib, acalabrutinib, and zanubrutinib achieve objective responses in the majority of patients as single agent therapy for relapsed MCL, but differ with regard to toxicity profile and dosing schedule. Lenalidomide and bortezomib are likewise approved for relapsed MCL and are active as monotherapy or in combination with other agents. Venetoclax has been used off-label for the treatment of relapsed and refractory MCL, however data are lacking regarding the efficacy of this approach particularly following BTKi treatment. Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies have emerged as highly effective therapy for relapsed MCL, with the CAR-T treatment brexucabtagene autoleucel now approved for relapsed MCL. In this review the authors summarize evidence to date for currently approved MCL treatments for relapsed disease including sequencing of therapies, and discuss future directions including combination treatment strategies and new therapies under investigation. Full article
(This article belongs to the Special Issue Advances in the Management of Aggressive Lymphomas)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop